Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on whatsapp
WhatsApp

An enormous progress in the treatment of metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer, TNBC, is the most aggressive type of breast cancer.

Once the disease becomes metastatic, life expectancy is around 12 to 15 months.

Triple Negative Breast Cancer, TNBC, does not have receptors for hormones and its cancer cells do not over express the protein HER2 (also called “ERBB2”) and so it cannot be treated with hormone therapy or drugs specifically targeting HER2. The main treatment is chemotherapy and most patients develop resistance to chemotherapy within a few months and their disease gets worsen.

902 patients were enrolled to the study in 303 cancer centers around the globe.

451 were treated with a combination of two drugs:

  1. An immunotherapy drug called “Tecentriq” which is approved of urothelial and lung cancers
  2. Abraxane” which a type of FDA approved chemotherapy usually used to treat pancreatic cancer.

All study participants received the treatments as first line for their metastatic disease, meaning at the earliest stage of the metastatic disease and not at later lines, after failure of several treatments.

The study name is “IMpassion130” and based on the following remarkable results, the FDA has granted an accelerated approval for the treatment of patients with Triple Negative Breast Cancer, TNBC, or unresectable locally advanced who are PD-L1–positive (>1%) with first line Tecentriq plus Abraxane:

It was possible to participate in this study from April 2015 and to benefit from this advanced and innovative treatment, almost four years before the FDA gave its official approval.

The true progress in cancer medicine lies in clinical trials. Do not settle for the regular treatments and standard protocols and always be certain that there are more treatments that can be offered to you even if you are told that there are not or you are not in the stage of clinical trials. Look what happened to those who participated in this study, she gained more, she lives longer.

For further reading

https://www.onclive.com/web-exclusives/fda-approves-atezolizumab-combo-for-frontline-tnbc

 

To get a personal free assessment to our service please in fill in your details and we will get back to you shortly

Improve therapeutic outcomes, prolong life and quality of life are our main business. We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics

Close Menu